Clinical trials: Bronchogenic Cancer
Lung Neoplasms, Thoracic Surgery
Comparison of Post-operative Pain and Quality of Life Between Subxiphoid and Intercostal VATS for Lung Cancer
One-thirds of patients underwent video-assisted thorascopic surgery (VATS) still have severe pain.Uniportal lobectomy or segmentectomies emerged as a promising and exciting approach for minimally invasive thoracic surgery.
- Conditions
- Lung Neoplasms, Thoracic Surgery, Carcinoma, Non-Small-Cell Lung, Lung Diseases
- Trial name
- NCT03331588
- Testing
- Subxiphoid uniportal VATS, Intercostal uniportal VATS
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Small Cell Lung Cancer (SCLC)
Spanish Real World Data on Patients Treated With Durvalumab After Chemoradiotherapy.
This is a non-interventional, observational, multicentre, one-arm, non-comparative, and retrospective study. The study is based on the collection of data about the patients treated with Durvalumab after chemoraditherapy in the…
- Trial name
- S-REAL (NCT04285866)
- Testing
- Durvalumab
- Where
- 39 sites in Spain
- Volunteers
- 245 people
- Sponsor
- Fundación GECP
Non-small-cell Lung Cancer
Effect of Exercise Training on Angiogenesis and Cachexia in Lung Cancer Patients
Cancer is one of the leading health issues in this country and worldwide. Angiogenesis is an essential process for tumoral growth and metastasis.
- Trial name
- NCT01136083
- Testing
- Exercise training, Usual care
- Where
- Taiwan
- Volunteers
- 60 people
- Sponsor
- National Taiwan University Hospital
Non-small Cell Lung Cancer
Tirellizumab Combined With Chemotherapy Monotherapy for Non-small Cell Lung Cancer
This is a prospective, single-arm, single-center, exploratory clinical trial to evaluate the efficacy and safety of the PD-1 antibody tirelizumab combined with chemotherapy monotherapy in patients with relapsed/metastatic…
- Trial name
- NCT05965102
- Testing
- Tirelizumab；Chemotherapy monotherapy
- Volunteers
- 31 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Non Small Cell Lung Cancer
Pathophysiological Mechanisms Involved in the Pronostic and Evolution of Non-Small Cell Lung Cancer (NSCLC) at All Stages of the Disease
This single-center observational cohort study conducted at Bordeaux University Hospital aims to establish a structured clinico-biological platform in non-small cell lung cancer (NSCLC) to investigate the biological mechanisms…
- Trial name
- EMA (NCT07470476)
- Testing
- Translational analyses
- Volunteers
- 150 people
- Sponsor
- University Hospital, Bordeaux
Non-small Cell Lung Cancer
Hypofractionated Radiotherapy Followed by Hypo-boost for Local Advanced NSCLC
The primary objective is to assess the safety and efficacy of hypofractionated radiotherapy followed by hypo-boost combined with concurrent weekly chemotherapy in unresectable LA-NSCLC patients.
- Trial name
- NCT03900117
- Testing
- split-course radiotherapy, concurrent chemotherapy
- Where
- China
- Volunteers
- 77 people
- Sponsor
- Sun Yat-sen University
Carcinoma, Non-Small-Cell Lung
CS-7017 in Combination With Erlotinib in Subjects With Stage IIIb/IV Non-small Cell Lung Cancer (NSCLC)
The primary objectives of this study are to evaluate the safety and tolerability of CS-7017 administered orally twice a day in combination with erlotinib, and to assess the pharmacokinetics of CS-7017 in combination with…
- Trial name
- NCT01199068
- Testing
- CS-7017, Erlotinib
- Where
- South Korea
- Volunteers
- 15 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Non-small Cell Lung Cancer (NSCLC), Brain Metastases
Furmonertinib 160mg vs 80mg + Chemotherapy in EGFR-Mutated NSCLC With Brain Metastases: Efficacy and Safety Study
This multicenter study evaluates the efficacy and safety of furmonertinib 160mg versus furmonertinib 80mg plus chemotherapy (carboplatin + pemetrexed) as first-line treatment for EGFR-mutated NSCLC patients with brain metastases.
- Conditions
- Non-small Cell Lung Cancer (NSCLC), Brain Metastases, Furmonertinib, EGFR Mutation
- Trial name
- NCT07365410
- Testing
- Furmonertinib, carboplatin, pemetrexed
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Esophageal Cancer, Non-small Cell Lung Cancer
Early Prediction of Pathology Response of Chemoradiotherapy With FLT PET
The goal of this research study is to learn if a new type of PET scan (18F-FLT) can help to better detect changes of tumor growth rate (or how active) in esophagus cancer and lung cancer Researchers will study at what time during…
- Trial name
- NCT01065818
- Testing
- Fluoro-L-Thymidine
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Columbia University
Non-Small Cell Lung Cancer
A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Following 4 Cycles of Platinum-based Chemotherapy Without Disease Progression
This open-label, single-arm study will evaluate the safety and efficacy of Tarceva (erlotinib) in patients with locally advanced or metastatic non-small cell lung cancer who have completed 4 cycles of standard platinum-based…
- Trial name
- NCT01230710
- Testing
- Erlotinib
- Where
- 7 sites in India
- Volunteers
- 51 people
- Sponsor
- Hoffmann-La Roche
Non-Small Cell Lung Cancer NSCLC
Clinical Study of Trop2 CAR-NK in the Treatment of Relapsed/Refractory Non-Small Cell Lung Cancer (NSCLC)
It is a single-center, open-labeled, single-arm, non-randomized investigator-initiated trial evaluating the efficacy and safety of anti-Trop2 U-CAR-NK Cells Therapy combined with Chemotherapy for Relapsed/Refractory Non-Small…
- Trial name
- NCT06454890
- Testing
- Anti-Trop2 CAR-NK cell
- Volunteers
- 50 people
- Sponsor
- Henan Cancer Hospital
Non Small Cell Lung Cancer, Metastatic Melanoma
UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade
This is a phase I/II study that will evaluate the safety and toxicity of this combinatorial approach. Eligible patients >18 years of age with histologically proven metastatic NSCLC, melanoma, RCC, or HNSCC who have failed PD-1 /…
- Conditions
- Non Small Cell Lung Cancer, Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT03474497
- Testing
- IL-2, Pembrolizumab, Radiotherapy
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- Megan Daly, MD
Non-Small Cell Lung Cancer
Study of Oxaliplatin and Gemcitabine With or Without Bevacizumab to Treat Advanced Non-Small Cell Lung Cancer
The combination of oxaliplatin and gemcitabine has proven activity in advanced non-small cell lung cancer (NSCLC). Due to its favorable toxicity profile, this combination is optimal for adding new agents.
- Trial name
- NCT00217282
- Testing
- oxaliplatin, gemcitabine, bevacizumab
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Mt. Sinai Medical Center, Miami
Small-cell Lung Cancer, Small Cell Lung Carcinoma
A Study of Olaparib and Low Dose Radiotherapy for Small Cell Lung Cancer
The purpose of this study is to test the safety of a new medication, Olaparib, combined with radiation therapy for participants with small cell lung cancer.
- Trial name
- NCT03532880
- Testing
- Olaparib Pill 50 mg, Olaparib Pill 100 mg, Olaparib Pill 150 mg
- Where
- 9 sites in United States
- Volunteers
- 26 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
EGFR Overexpression, Locally Advanced Solid Tumor
Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid Tumors
This is a study for people with locally advanced or metastatic cancer for whom previous treatment was not successful. Adults aged 18 and over with advanced cancer with Epidermal Growth Factor Receptor (EGFR) overexpressing can…
- Conditions
- EGFR Overexpression, Locally Advanced Solid Tumor, Metastatic Solid Tumor
- Trial name
- NCT06975410
- Testing
- YH32364
- Where
- 4 sites in South Korea
- Volunteers
- 80 people
- Sponsor
- Yuhan Corporation
Carcinoma, Non-small Cell Lung
Phase I Imaging Study Evaluating Dalotuzumab (MK0646) in Combination With Erlotinib for Patients With Non-Small Cell Lung Cancer (MK-0646-008)
This study will use imaging to look at tumor response to erlotinib (Part I) and the combination of erlotinib and dalotuzumab (Part II).
- Trial name
- NCT00729742
- Testing
- Comparator: erlotinib + dalotuzumab, Comparator: erlotinib monotherapy
- Volunteers
- 49 people
- Sponsor
- Merck Sharp & Dohme LLC
Lung Cancer
Docetaxel and Cisplatin in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer That Has Been Completely Removed By Surgery
RATIONALE: Drugs used in chemotherapy, such as docetaxel and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00281970
- Testing
- cisplatin, docetaxel, adjuvant therapy
- Where
- 3 sites in United States
- Volunteers
- 50 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Carcinoma, Non-Small-Cell Lung, Brain Metastases
Lorlatinib in Patients With ALK-Positive NSCLC With Brain or Leptomeningeal Metastases
This study is an investigator-initiated, prospective, open-label, single-arm, multicenter clinical trial aimed at exploring the antitumor activity of Lorlatinib in ALK-positive NSCLC patients with brain/ leptomeningeal metastases.
- Conditions
- Carcinoma, Non-Small-Cell Lung, Brain Metastases, Leptomeningeal Metastasis
- Trial name
- NCT06282874
- Testing
- Lorlatinib
- Where
- 3 sites in China
- Volunteers
- 41 people
- Sponsor
- Guangdong Association of Clinical Trials
Lung Cancer (NSCLC)
Navigation Bronchoscopy Guided Microwave Ablation Versus SBRT in Early NSCLC
Background: Stereotactic body radiotherapy (SBRT) is a standard definitive local therapy for medically inoperable early stage non-small cell lung cancer (NSCLC).
- Trial name
- NCT07722182
- Testing
- Navigation Bronchoscopy-Guided Microwave Ablation, Stereotactic Body Radiotherapy (SBRT)
- Where
- Hong Kong
- Volunteers
- 100 people
- Sponsor
- Chinese University of Hong Kong
Carcinoma, Non-small Cell Lung
Single Agent Versus Combination Chemotherapy to Treat High-risk Elderly With Non-small Cell Lung Cancer
This study will enroll elderly patients with advanced non-small cell lung cancer who are at high risk of developing chemotherapy toxicity (side effects).
- Trial name
- NCT02590003
- Testing
- Carboplatin, Nab-paclitaxel
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Yale University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.